{
 "cells": [
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "# End-to-End Example",
   "id": "cf0be1ddc2bd2434"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "%%capture\n",
    "%pip install fsspec langchain-text-splitters openai python-dotenv numpy torch"
   ],
   "id": "9820f541adf30bfd",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": "",
   "id": "3e7118392f43093",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "%%capture\n",
    "%pip install -U git+https://github.com/neo4j/neo4j-graphrag-python"
   ],
   "id": "aa9e401e2305fb0",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "#%capture\n",
    "#%pip install -U ../demo/neo4j-graphrag-python"
   ],
   "id": "fa8a46520d565af0",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:40:41.314857Z",
     "start_time": "2024-10-04T03:40:41.305735Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "# load neo4j credentials (and openai api key in background)\n",
    "load_dotenv('.env', override=True)\n",
    "NEO4J_URI = os.getenv('NEO4J_URI')\n",
    "NEO4J_USERNAME = os.getenv('NEO4J_USERNAME')\n",
    "NEO4J_PASSWORD = os.getenv('NEO4J_PASSWORD')\n",
    "\n",
    "pdf_file_path = \"pgpm-13-39.pdf\""
   ],
   "id": "a023c71324bf6e7f",
   "outputs": [],
   "execution_count": 1
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "## KG Building\n",
   "id": "418bd212bae7f492"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:40:57.209426Z",
     "start_time": "2024-10-04T03:40:56.504910Z"
    }
   },
   "cell_type": "code",
   "source": [
    "import neo4j\n",
    "from neo4j_graphrag.llm import OpenAILLM\n",
    "\n",
    "driver = neo4j.GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USERNAME, NEO4J_PASSWORD))\n",
    "\n",
    "extractor_llm=OpenAILLM(\n",
    "    model_name=\"gpt-4o-mini\",\n",
    "    model_params={\n",
    "        \"max_tokens\": 16_000,\n",
    "        \"response_format\": {\"type\": \"json_object\"}, # use json_object formatting for best results\n",
    "        \"temperature\": 0 # turning temperature down for more deterministic results\n",
    "    }\n",
    ")"
   ],
   "id": "fd60a2f512b9701d",
   "outputs": [],
   "execution_count": 2
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:40:57.224679Z",
     "start_time": "2024-10-04T03:40:57.210231Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.experimental.components.schema import (\n",
    "    SchemaEntity,\n",
    "    SchemaProperty,\n",
    "    SchemaRelation,\n",
    ")\n",
    "\n",
    "# define entity types (a.k.a node labels)\n",
    "basic_node_labels = [\"Object\",\n",
    "                     \"Entity\",\n",
    "                     \"Group\",\n",
    "                     \"Person\",\n",
    "                     \"Organization\",\n",
    "                     \"Place\"\n",
    "                     ]\n",
    "academic_node_labels = [\"ArticleOrPaper\",\n",
    "                        \"PublicationOrJournal\"]\n",
    "\n",
    "medical_node_labels = [\"Anatomy\",\n",
    "                       \"BiologicalProcess\",\n",
    "                       \"Cell\",\n",
    "                       \"CellularComponent\",\n",
    "                       \"CellType\",\n",
    "                       \"Condition\",\n",
    "                       \"Disease\",\n",
    "                       \"Drug\",\n",
    "                       \"EffectOrPhenotype\",\n",
    "                       \"Exposure\",\n",
    "                       \"GeneOrProtein\",\n",
    "                       \"Molecule\",\n",
    "                       \"MolecularFunction\",\n",
    "                       \"Pathway\"]\n",
    "\n",
    "node_labels = basic_node_labels + academic_node_labels + medical_node_labels\n",
    "\n",
    "# define relationship types (a.k.a how entities can be related)\n",
    "rel_types = [\"ACTIVATES\",\n",
    "             \"AFFECTS\",\n",
    "             \"ASSESSES\",\n",
    "             \"ASSOCIATED_WITH\",\n",
    "             \"AUTHORED\",\n",
    "             \"CAUSES\",\n",
    "             \"CITES\",\n",
    "             \"CLASSIFIES\",\n",
    "             \"COLLABORATES_WITH\"\n",
    "             \"CONTRIBUTES_TO\",\n",
    "             \"CORRELATES_WITH\",\n",
    "             \"DESCRIBES\",\n",
    "             \"DEVELOPED\",\n",
    "             \"DISCUSSES\",\n",
    "             \"EXHIBITS\",\n",
    "             \"EXPRESSES\",\n",
    "             \"HAS_EFFECT\",\n",
    "             \"HAS_SYMPTOM\",\n",
    "             \"INCLUDES\",\n",
    "             \"INDUCES\",\n",
    "             \"INTERACTS_WITH\",\n",
    "             \"INVOLVES\",\n",
    "             \"LEADS_TO\",\n",
    "             \"LINKED_TO\",\n",
    "             \"LOCATED_IN\",\n",
    "             \"MANIFESTS_AS\",\n",
    "             \"OBSERVED_IN\",\n",
    "             \"PARTICIPATES_IN\",\n",
    "             \"PART_OF\",\n",
    "             \"PRODUCES\",\n",
    "             \"PUBLISHED_IN\",\n",
    "             \"REACTS_WITH\",\n",
    "             \"REDUCES\",\n",
    "             \"RELATED_TO\",\n",
    "             \"RESULTS_IN\",\n",
    "             \"TARGETS\",\n",
    "             \"TREATMENT_FOR\",\n",
    "             \"TRIGGERS\",\n",
    "             \"USED_FOR\",\n",
    "             \"USED_WITH\",\n",
    "             \"USES\"]\n",
    "\n",
    "\n",
    "# define properties. In this case we will allow for the same two properties on both nodes and relationships. \n",
    "properties = [SchemaProperty(name=\"name\", type=\"STRING\"), SchemaProperty(name=\"details\", type=\"STRING\")]\n",
    "\n",
    "# build the schema objects\n",
    "\n",
    "entities = [SchemaEntity(label=i, properties=properties) for i in node_labels],\n",
    "relations = [SchemaRelation(label=i, properties=properties) for i in rel_types],\n",
    "potential_schema = [] #this can be used to define which relationships types should connect to which entity types. We skip here, but recommended for refining knowledge graphs. \n"
   ],
   "id": "6cba83fa4638e21d",
   "outputs": [],
   "execution_count": 3
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:40:57.824265Z",
     "start_time": "2024-10-04T03:40:57.821860Z"
    }
   },
   "cell_type": "code",
   "source": [
    "prompt_template = '''\n",
    "You are a medical researcher tasks with extracting information from papers \n",
    "and structuring it in a property graph to inform further medical and research Q&A\n",
    "\n",
    "Extract the entities (nodes) and specify their type from the following Input text.\n",
    "Also extract the relationships between these nodes. the relationship direction goes from the start node to the end node. \n",
    "\n",
    "\n",
    "Return result as JSON using the following format:\n",
    "{{\"nodes\": [ {{\"id\": \"0\", \"label\": \"the type of entity\", \"properties\": {{\"name\": \"name of entity\", \"details\":\" brief description of entity (dont include info about relationships)\" }} }}],\n",
    "  \"relationships\": [{{\"type\": \"TYPE_OF_RELATIONSHIP\", \"start_node_id\": \"0\", \"end_node_id\": \"1\", \"properties\": {{\"details\": \"brief description of relationship if needed\"}} }}] }}\n",
    "\n",
    "Use only the information from the Input text.  Do not add any additional information.  If the input text is empty, return empty Json. \n",
    "Make sure to create as many nodes and relationships as needed to offer rich medical context for further research.\n",
    "An AI knowledge assistant must be able to read this graph and immediately understand the context to inform detailed research questions. \n",
    "\n",
    "Use only fhe following nodes and relationships (if provided):\n",
    "{schema}\n",
    "\n",
    "Assign a unique ID (string) to each node, and reuse it to define relationships.\n",
    "Do respect the source and target node types for relationship and\n",
    "the relationship direction.\n",
    "\n",
    "Do not return any additional information other than the JSON in it.\n",
    "\n",
    "Examples:\n",
    "{examples}\n",
    "\n",
    "Input text:\n",
    "\n",
    "{text}\n",
    "'''"
   ],
   "id": "8cbcdedcd1757b1d",
   "outputs": [],
   "execution_count": 4
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:41:00.330946Z",
     "start_time": "2024-10-04T03:40:59.033622Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from langchain_text_splitters import CharacterTextSplitter\n",
    "from neo4j_graphrag.experimental.components.text_splitters.langchain import LangChainTextSplitterAdapter\n",
    "from neo4j_graphrag.experimental.pipeline.kg_builder import SimpleKGPipeline\n",
    "\n",
    "kg_builder_pdf = SimpleKGPipeline(\n",
    "    llm=extractor_llm,\n",
    "    driver=driver,\n",
    "    entities=node_labels,\n",
    "    relations=rel_types,\n",
    "    potential_schema=potential_schema,\n",
    "    prompt_template=prompt_template,\n",
    "    text_splitter=LangChainTextSplitterAdapter(CharacterTextSplitter(chunk_size=500, chunk_overlap=100, separator=\".\")),\n",
    "    from_pdf=True\n",
    ")"
   ],
   "id": "94e1dfac980e6527",
   "outputs": [],
   "execution_count": 5
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:45:25.763472Z",
     "start_time": "2024-10-04T03:41:01.075726Z"
    }
   },
   "cell_type": "code",
   "source": [
    "pdf_result = await kg_builder_pdf.run_async(file_path=pdf_file_path)\n",
    "print(f\"PDF Processing Result: {pdf_result}\")"
   ],
   "id": "edeee98826a970a8",
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Created a chunk of size 563, which is longer than the specified 500\n",
      "Created a chunk of size 646, which is longer than the specified 500\n",
      "Created a chunk of size 732, which is longer than the specified 500\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (n, row) { ... }} {position: line: 1, column: 168, offset: 167} for query: 'UNWIND $rows AS row CREATE (n:__KGBuilder__ {id: row.id}) SET n += row.properties WITH n, row CALL apoc.create.addLabels(n, row.labels) YIELD node WITH node as n, row CALL { WITH n, row WITH n, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setNodeVectorProperty(n, emb, row.embedding_properties[emb]) RETURN count(*) as nbEmb } RETURN elementId(n)'\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (n, row) { ... }} {position: line: 1, column: 168, offset: 167} for query: 'UNWIND $rows AS row CREATE (n:__KGBuilder__ {id: row.id}) SET n += row.properties WITH n, row CALL apoc.create.addLabels(n, row.labels) YIELD node WITH node as n, row CALL { WITH n, row WITH n, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setNodeVectorProperty(n, emb, row.embedding_properties[emb]) RETURN count(*) as nbEmb } RETURN elementId(n)'\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (rel, row) { ... }} {position: line: 1, column: 254, offset: 253} for query: 'UNWIND $rows as row MATCH (start:__KGBuilder__ {id: row.start_node_id}) MATCH (end:__KGBuilder__ {id: row.end_node_id}) WITH start, end, row CALL apoc.merge.relationship(start, row.type, {}, row.properties, end, row.properties) YIELD rel  WITH rel, row CALL { WITH rel, row WITH rel, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setRelationshipVectorProperty(rel, emb, row.embedding_properties[emb]) } RETURN elementId(rel)'\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (rel, row) { ... }} {position: line: 1, column: 254, offset: 253} for query: 'UNWIND $rows as row MATCH (start:__KGBuilder__ {id: row.start_node_id}) MATCH (end:__KGBuilder__ {id: row.end_node_id}) WITH start, end, row CALL apoc.merge.relationship(start, row.type, {}, row.properties, end, row.properties) YIELD rel  WITH rel, row CALL { WITH rel, row WITH rel, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setRelationshipVectorProperty(rel, emb, row.embedding_properties[emb]) } RETURN elementId(rel)'\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (rel, row) { ... }} {position: line: 1, column: 254, offset: 253} for query: 'UNWIND $rows as row MATCH (start:__KGBuilder__ {id: row.start_node_id}) MATCH (end:__KGBuilder__ {id: row.end_node_id}) WITH start, end, row CALL apoc.merge.relationship(start, row.type, {}, row.properties, end, row.properties) YIELD rel  WITH rel, row CALL { WITH rel, row WITH rel, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setRelationshipVectorProperty(rel, emb, row.embedding_properties[emb]) } RETURN elementId(rel)'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PDF Processing Result: run_id='ae54d809-a9c6-4953-984e-45e3c288f6e2' result={'resolver': {'number_of_nodes_to_resolve': 1041, 'number_of_created_nodes': 854}}\n"
     ]
    }
   ],
   "execution_count": 6
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:45:28.170358Z",
     "start_time": "2024-10-04T03:45:25.765445Z"
    }
   },
   "cell_type": "code",
   "source": [
    "with neo4j.GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USERNAME, NEO4J_PASSWORD)) as driver:\n",
    "    with driver.session(database=\"neo4j\") as session:\n",
    "        session.run('''\n",
    "        MATCH (n:Chunk) WHERE size(n.text) <> 0\n",
    "        WITH collect(n) AS nodes, toInteger(rand()*$numberOfBatches) AS partition\n",
    "        CALL (nodes){\n",
    "            CALL genai.vector.encodeBatch([node IN nodes| node.text], \"OpenAI\", { token: $token})\n",
    "            YIELD index, vector\n",
    "            CALL db.create.setNodeVectorProperty(nodes[index], \"embedding\", vector)\n",
    "        } IN TRANSACTIONS OF 1 ROW''', parameters={'token':os.getenv('OPENAI_API_KEY'), 'numberOfBatches':2})"
   ],
   "id": "e86545113f04266d",
   "outputs": [],
   "execution_count": 7
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "## KG Retrieval\n",
    "Now lets make some knowledge graph retrievers which we will later use for a GraphRAG pipeline"
   ],
   "id": "a9c0fd965b15b143"
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "We will leverage Neo4j's vector search capabilities here. To do this we need to begin by creating a vector index on the text in our CHunk nodes",
   "id": "4d7b98e310104246"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:51:40.943751Z",
     "start_time": "2024-10-04T03:51:39.614192Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.indexes import create_vector_index\n",
    "\n",
    "create_vector_index(driver, name=\"text_embeddings\", label=\"Chunk\", embedding_property=\"embedding\", dimensions=1536, similarity_fn=\"cosine\")"
   ],
   "id": "940b051107b89204",
   "outputs": [
    {
     "ename": "Neo4jIndexError",
     "evalue": "Neo4j vector index creation failed: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'.",
     "output_type": "error",
     "traceback": [
      "\u001B[0;31m---------------------------------------------------------------------------\u001B[0m",
      "\u001B[0;31mClientError\u001B[0m                               Traceback (most recent call last)",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j_graphrag/indexes.py:112\u001B[0m, in \u001B[0;36mcreate_vector_index\u001B[0;34m(driver, name, label, embedding_property, dimensions, similarity_fn, neo4j_database)\u001B[0m\n\u001B[1;32m    111\u001B[0m     logger\u001B[38;5;241m.\u001B[39minfo(\u001B[38;5;124mf\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mCreating vector index named \u001B[39m\u001B[38;5;124m'\u001B[39m\u001B[38;5;132;01m{\u001B[39;00mname\u001B[38;5;132;01m}\u001B[39;00m\u001B[38;5;124m'\u001B[39m\u001B[38;5;124m\"\u001B[39m)\n\u001B[0;32m--> 112\u001B[0m     driver\u001B[38;5;241m.\u001B[39mexecute_query(\n\u001B[1;32m    113\u001B[0m         query,\n\u001B[1;32m    114\u001B[0m         {\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mname\u001B[39m\u001B[38;5;124m\"\u001B[39m: name, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mdimensions\u001B[39m\u001B[38;5;124m\"\u001B[39m: dimensions, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124msimilarity_fn\u001B[39m\u001B[38;5;124m\"\u001B[39m: similarity_fn},\n\u001B[1;32m    115\u001B[0m         database_\u001B[38;5;241m=\u001B[39mneo4j_database,\n\u001B[1;32m    116\u001B[0m     )\n\u001B[1;32m    117\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m neo4j\u001B[38;5;241m.\u001B[39mexceptions\u001B[38;5;241m.\u001B[39mClientError \u001B[38;5;28;01mas\u001B[39;00m e:\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/driver.py:959\u001B[0m, in \u001B[0;36mDriver.execute_query\u001B[0;34m(self, query_, parameters_, routing_, database_, impersonated_user_, bookmark_manager_, auth_, result_transformer_, **kwargs)\u001B[0m\n\u001B[1;32m    958\u001B[0m \u001B[38;5;28;01mwith\u001B[39;00m session\u001B[38;5;241m.\u001B[39m_pipelined_begin:\n\u001B[0;32m--> 959\u001B[0m     \u001B[38;5;28;01mreturn\u001B[39;00m session\u001B[38;5;241m.\u001B[39m_run_transaction(\n\u001B[1;32m    960\u001B[0m         access_mode, TelemetryAPI\u001B[38;5;241m.\u001B[39mDRIVER,\n\u001B[1;32m    961\u001B[0m         work, (query_str, parameters, result_transformer_), {}\n\u001B[1;32m    962\u001B[0m     )\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/session.py:554\u001B[0m, in \u001B[0;36mSession._run_transaction\u001B[0;34m(self, access_mode, api, transaction_function, args, kwargs)\u001B[0m\n\u001B[1;32m    553\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 554\u001B[0m     result \u001B[38;5;241m=\u001B[39m transaction_function(tx, \u001B[38;5;241m*\u001B[39margs, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwargs)\n\u001B[1;32m    555\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m asyncio\u001B[38;5;241m.\u001B[39mCancelledError:\n\u001B[1;32m    556\u001B[0m     \u001B[38;5;66;03m# if cancellation callback has not been called yet:\u001B[39;00m\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/driver.py:1290\u001B[0m, in \u001B[0;36m_work\u001B[0;34m(tx, query, parameters, transformer)\u001B[0m\n\u001B[1;32m   1284\u001B[0m \u001B[38;5;28;01mdef\u001B[39;00m \u001B[38;5;21m_work\u001B[39m(\n\u001B[1;32m   1285\u001B[0m     tx: ManagedTransaction,\n\u001B[1;32m   1286\u001B[0m     query: te\u001B[38;5;241m.\u001B[39mLiteralString,\n\u001B[1;32m   1287\u001B[0m     parameters: t\u001B[38;5;241m.\u001B[39mDict[\u001B[38;5;28mstr\u001B[39m, t\u001B[38;5;241m.\u001B[39mAny],\n\u001B[1;32m   1288\u001B[0m     transformer: t\u001B[38;5;241m.\u001B[39mCallable[[Result], t\u001B[38;5;241m.\u001B[39mUnion[_T]]\n\u001B[1;32m   1289\u001B[0m ) \u001B[38;5;241m-\u001B[39m\u001B[38;5;241m>\u001B[39m _T:\n\u001B[0;32m-> 1290\u001B[0m     res \u001B[38;5;241m=\u001B[39m tx\u001B[38;5;241m.\u001B[39mrun(query, parameters)\n\u001B[1;32m   1291\u001B[0m     \u001B[38;5;28;01mreturn\u001B[39;00m transformer(res)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/transaction.py:172\u001B[0m, in \u001B[0;36mTransactionBase.run\u001B[0;34m(self, query, parameters, **kwparameters)\u001B[0m\n\u001B[1;32m    171\u001B[0m parameters \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mdict\u001B[39m(parameters \u001B[38;5;129;01mor\u001B[39;00m {}, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwparameters)\n\u001B[0;32m--> 172\u001B[0m result\u001B[38;5;241m.\u001B[39m_tx_ready_run(query, parameters)\n\u001B[1;32m    174\u001B[0m \u001B[38;5;28;01mreturn\u001B[39;00m result\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:171\u001B[0m, in \u001B[0;36mResult._tx_ready_run\u001B[0;34m(self, query, parameters)\u001B[0m\n\u001B[1;32m    167\u001B[0m \u001B[38;5;28;01mdef\u001B[39;00m \u001B[38;5;21m_tx_ready_run\u001B[39m(\u001B[38;5;28mself\u001B[39m, query, parameters):\n\u001B[1;32m    168\u001B[0m     \u001B[38;5;66;03m# BEGIN+RUN does not carry any extra on the RUN message.\u001B[39;00m\n\u001B[1;32m    169\u001B[0m     \u001B[38;5;66;03m# BEGIN {extra}\u001B[39;00m\n\u001B[1;32m    170\u001B[0m     \u001B[38;5;66;03m# RUN \"query\" {parameters} {extra}\u001B[39;00m\n\u001B[0;32m--> 171\u001B[0m     \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_run(query, parameters, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:221\u001B[0m, in \u001B[0;36mResult._run\u001B[0;34m(self, query, parameters, db, imp_user, access_mode, bookmarks, notifications_min_severity, notifications_disabled_classifications)\u001B[0m\n\u001B[1;32m    220\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_connection\u001B[38;5;241m.\u001B[39msend_all()\n\u001B[0;32m--> 221\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_attach()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:409\u001B[0m, in \u001B[0;36mResult._attach\u001B[0;34m(self)\u001B[0m\n\u001B[1;32m    408\u001B[0m \u001B[38;5;28;01mwhile\u001B[39;00m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_attached \u001B[38;5;129;01mis\u001B[39;00m \u001B[38;5;28;01mFalse\u001B[39;00m:\n\u001B[0;32m--> 409\u001B[0m     \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_connection\u001B[38;5;241m.\u001B[39mfetch_message()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_common.py:178\u001B[0m, in \u001B[0;36mConnectionErrorHandler.__getattr__.<locals>.outer.<locals>.inner\u001B[0;34m(*args, **kwargs)\u001B[0m\n\u001B[1;32m    177\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 178\u001B[0m     func(\u001B[38;5;241m*\u001B[39margs, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwargs)\n\u001B[1;32m    179\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m (Neo4jError, ServiceUnavailable, SessionExpired) \u001B[38;5;28;01mas\u001B[39;00m exc:\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_bolt.py:860\u001B[0m, in \u001B[0;36mBolt.fetch_message\u001B[0;34m(self)\u001B[0m\n\u001B[1;32m    857\u001B[0m tag, fields \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39minbox\u001B[38;5;241m.\u001B[39mpop(\n\u001B[1;32m    858\u001B[0m     hydration_hooks\u001B[38;5;241m=\u001B[39m\u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39mresponses[\u001B[38;5;241m0\u001B[39m]\u001B[38;5;241m.\u001B[39mhydration_hooks\n\u001B[1;32m    859\u001B[0m )\n\u001B[0;32m--> 860\u001B[0m res \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_process_message(tag, fields)\n\u001B[1;32m    861\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39midle_since \u001B[38;5;241m=\u001B[39m monotonic()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_bolt5.py:370\u001B[0m, in \u001B[0;36mBolt5x0._process_message\u001B[0;34m(self, tag, fields)\u001B[0m\n\u001B[1;32m    369\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 370\u001B[0m     response\u001B[38;5;241m.\u001B[39mon_failure(summary_metadata \u001B[38;5;129;01mor\u001B[39;00m {})\n\u001B[1;32m    371\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m (ServiceUnavailable, DatabaseUnavailable):\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_common.py:245\u001B[0m, in \u001B[0;36mResponse.on_failure\u001B[0;34m(self, metadata)\u001B[0m\n\u001B[1;32m    244\u001B[0m Util\u001B[38;5;241m.\u001B[39mcallback(handler)\n\u001B[0;32m--> 245\u001B[0m \u001B[38;5;28;01mraise\u001B[39;00m Neo4jError\u001B[38;5;241m.\u001B[39mhydrate(\u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mmetadata)\n",
      "\u001B[0;31mClientError\u001B[0m: {code: Neo.ClientError.Schema.EquivalentSchemaRuleAlreadyExists} {message: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'.}",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001B[0;31mNeo4jIndexError\u001B[0m                           Traceback (most recent call last)",
      "Cell \u001B[0;32mIn[8], line 3\u001B[0m\n\u001B[1;32m      1\u001B[0m \u001B[38;5;28;01mfrom\u001B[39;00m \u001B[38;5;21;01mneo4j_graphrag\u001B[39;00m\u001B[38;5;21;01m.\u001B[39;00m\u001B[38;5;21;01mindexes\u001B[39;00m \u001B[38;5;28;01mimport\u001B[39;00m create_vector_index\n\u001B[0;32m----> 3\u001B[0m create_vector_index(driver, name\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mtext_embeddings\u001B[39m\u001B[38;5;124m\"\u001B[39m, label\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mChunk\u001B[39m\u001B[38;5;124m\"\u001B[39m, embedding_property\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124membedding\u001B[39m\u001B[38;5;124m\"\u001B[39m, dimensions\u001B[38;5;241m=\u001B[39m\u001B[38;5;241m1536\u001B[39m, similarity_fn\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mcosine\u001B[39m\u001B[38;5;124m\"\u001B[39m)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j_graphrag/indexes.py:118\u001B[0m, in \u001B[0;36mcreate_vector_index\u001B[0;34m(driver, name, label, embedding_property, dimensions, similarity_fn, neo4j_database)\u001B[0m\n\u001B[1;32m    112\u001B[0m     driver\u001B[38;5;241m.\u001B[39mexecute_query(\n\u001B[1;32m    113\u001B[0m         query,\n\u001B[1;32m    114\u001B[0m         {\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mname\u001B[39m\u001B[38;5;124m\"\u001B[39m: name, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mdimensions\u001B[39m\u001B[38;5;124m\"\u001B[39m: dimensions, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124msimilarity_fn\u001B[39m\u001B[38;5;124m\"\u001B[39m: similarity_fn},\n\u001B[1;32m    115\u001B[0m         database_\u001B[38;5;241m=\u001B[39mneo4j_database,\n\u001B[1;32m    116\u001B[0m     )\n\u001B[1;32m    117\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m neo4j\u001B[38;5;241m.\u001B[39mexceptions\u001B[38;5;241m.\u001B[39mClientError \u001B[38;5;28;01mas\u001B[39;00m e:\n\u001B[0;32m--> 118\u001B[0m     \u001B[38;5;28;01mraise\u001B[39;00m Neo4jIndexError(\u001B[38;5;124mf\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mNeo4j vector index creation failed: \u001B[39m\u001B[38;5;132;01m{\u001B[39;00me\u001B[38;5;241m.\u001B[39mmessage\u001B[38;5;132;01m}\u001B[39;00m\u001B[38;5;124m\"\u001B[39m) \u001B[38;5;28;01mfrom\u001B[39;00m \u001B[38;5;21;01me\u001B[39;00m\n",
      "\u001B[0;31mNeo4jIndexError\u001B[0m: Neo4j vector index creation failed: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'."
     ]
    }
   ],
   "execution_count": 8
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Now that the index is set up we will start simple with a VectorRetriever.  The VectorRetriever just queries Chunk nodes, brining back the text and some metadata",
   "id": "ec95391c989ee694"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:51:44.397940Z",
     "start_time": "2024-10-04T03:51:44.072557Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorRetriever\n",
    "\n",
    "from neo4j_graphrag.embeddings.openai import OpenAIEmbeddings\n",
    "\n",
    "embedder = OpenAIEmbeddings()\n",
    "\n",
    "vector_retriever = VectorRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    return_properties=[\"text\"],\n",
    ")"
   ],
   "id": "eeda7e519c60a02b",
   "outputs": [],
   "execution_count": 9
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:51:45.294590Z",
     "start_time": "2024-10-04T03:51:44.749941Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vector_res = vector_retriever.get_search_results(query_text = \"Which biomarkers are associated with predicting organ damage in lupus patients?\")\n",
    "\n",
    "for i in vector_res.records: print(\"====\\n\" + i.data()['node']['text'])"
   ],
   "id": "ca27731a1f99d71d",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====\n",
      "Ideally every\n",
      "patient would undergo an initial evaluation that would\n",
      "proﬁle his/her disease, assessing the main pathophysiolo-\n",
      "gic pathway through biomarkers, therefore predicting risk\n",
      "of speci ﬁc organ damage, most adequate treatment, and\n",
      "would allow better follow-up and ﬂare prediction.\n",
      "In this review, we will outline the pathological processes\n",
      "in lupus in general terms with particular emphasis on neu-\n",
      "ropsychiatric and renal involvement\n",
      "====\n",
      "2017 ;43:531 –548. doi:10.1016/j.rdc.2017.06.003\n",
      "49. Hanly J, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for\n",
      "the prediction of neuropsychiatric events in systemic lupus\n",
      "erythematosus. Ann Rheum Dis .2011 ;10:1726 –1732. doi:10.1136/\n",
      "ard.2010.148502\n",
      "50. McGlasson S, Wiseman S, Wardlaw J, Dhaun N, Hunt DPJ.\n",
      "Neurological disease in lupus: toward a personalized medicine\n",
      "approach. Front Immunol .2018 ;9(1146):1 –12. doi:10.3389/ ﬁmmu.\n",
      "2018.01146\n",
      "51. Tchessalova D, Posillico CK, Tronson NC\n",
      "====\n",
      "Use of blood\n",
      "markers notably anti-dsDNA antibody levels [which increase\n",
      "with active disease] or C3 levels [which fall when the disease\n",
      "is active] provide help to the clinician when assessing disease\n",
      "activity. Scoring is determined based on new, improving,\n",
      "worse and similar categories. The art of the physician is to\n",
      "identify the activity features clinically and apply the appro-\n",
      "priate management. Renal lupus can, rarely, be active without\n",
      "the presence of other SLE disease involvement\n",
      "====\n",
      "2018 ;70:1801 –1806.\n",
      "doi:10.1002/art.40575\n",
      "43. Arazi A, Rao DA, Berthier CC etal,. The immune cell landscape in\n",
      "kidneys of patients with lupus nephritis. Nat Immunol .\n",
      "2019 ;20:902 –914. doi:10.1038/s41590-019-0398-x\n",
      "44. Yung S, Chan TM. Anti-dsDNA antibodies and resident renal cells -\n",
      "Their putative roles in pathogenesis of renal lesions in lupus nephritis.\n",
      "Clin Immunol .2017 ;185:40 –50 . doi:10.1016/j.clim.2016.09.002\n",
      "45. Nalewajska M, Gurazda K, Styczy ńska-Kowalska E, et al\n",
      "====\n",
      "Lever et al Dove press\n",
      "submit your manuscript | www.dovepress.com\n",
      "Dove PressPharmacogenomics and Personalized Medicine 2020:13 44\n",
      "better than other forms [e.g., subacute and chronic]. Severe\n",
      "life-threatening lupus with renal or neuropsychiatric involve-\n",
      "ment is treated with potent agents notably cyclophosphamide.\n",
      "BILAG grading and following the pattern over time assists in\n",
      "determining the degree of immunosuppression\n"
     ]
    }
   ],
   "execution_count": 10
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:51:47.649598Z",
     "start_time": "2024-10-04T03:51:47.645381Z"
    }
   },
   "cell_type": "code",
   "source": "vector_res",
   "id": "bb6000cd377d6d16",
   "outputs": [
    {
     "data": {
      "text/plain": [
       "RawSearchResult(records=[<Record node={'text': 'Ideally every\\npatient would undergo an initial evaluation that would\\nproﬁle his/her disease, assessing the main pathophysiolo-\\ngic pathway through biomarkers, therefore predicting risk\\nof speci ﬁc organ damage, most adequate treatment, and\\nwould allow better follow-up and ﬂare prediction.\\nIn this review, we will outline the pathological processes\\nin lupus in general terms with particular emphasis on neu-\\nropsychiatric and renal involvement'} score=0.93621826171875>, <Record node={'text': '2017 ;43:531 –548. doi:10.1016/j.rdc.2017.06.003\\n49. Hanly J, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for\\nthe prediction of neuropsychiatric events in systemic lupus\\nerythematosus. Ann Rheum Dis .2011 ;10:1726 –1732. doi:10.1136/\\nard.2010.148502\\n50. McGlasson S, Wiseman S, Wardlaw J, Dhaun N, Hunt DPJ.\\nNeurological disease in lupus: toward a personalized medicine\\napproach. Front Immunol .2018 ;9(1146):1 –12. doi:10.3389/ ﬁmmu.\\n2018.01146\\n51. Tchessalova D, Posillico CK, Tronson NC'} score=0.9256744384765625>, <Record node={'text': 'Use of blood\\nmarkers notably anti-dsDNA antibody levels [which increase\\nwith active disease] or C3 levels [which fall when the disease\\nis active] provide help to the clinician when assessing disease\\nactivity. Scoring is determined based on new, improving,\\nworse and similar categories. The art of the physician is to\\nidentify the activity features clinically and apply the appro-\\npriate management. Renal lupus can, rarely, be active without\\nthe presence of other SLE disease involvement'} score=0.91796875>, <Record node={'text': '2018 ;70:1801 –1806.\\ndoi:10.1002/art.40575\\n43. Arazi A, Rao DA, Berthier CC etal,. The immune cell landscape in\\nkidneys of patients with lupus nephritis. Nat Immunol .\\n2019 ;20:902 –914. doi:10.1038/s41590-019-0398-x\\n44. Yung S, Chan TM. Anti-dsDNA antibodies and resident renal cells -\\nTheir putative roles in pathogenesis of renal lesions in lupus nephritis.\\nClin Immunol .2017 ;185:40 –50 . doi:10.1016/j.clim.2016.09.002\\n45. Nalewajska M, Gurazda K, Styczy ńska-Kowalska E, et al'} score=0.9176025390625>, <Record node={'text': 'Lever et al Dove press\\nsubmit your manuscript | www.dovepress.com\\nDove PressPharmacogenomics and Personalized Medicine 2020:13 44\\nbetter than other forms [e.g., subacute and chronic]. Severe\\nlife-threatening lupus with renal or neuropsychiatric involve-\\nment is treated with potent agents notably cyclophosphamide.\\nBILAG grading and following the pattern over time assists in\\ndetermining the degree of immunosuppression'} score=0.9170684814453125>], metadata=None)"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 11
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "The GraphRAG Python Package offers a whole host of other useful retrieval covering different graphRAG patterns (link) including (examples).  and if none of those fit perfectly you can impliment your own custom retrievers (link). \n",
    "\n",
    "Below we will use the VectorCypherRetriever which allows you to run a graph traversal after finding text chunks.  We will use the Cypher Query language (link) to define the logic to traverse the graph.  \n",
    "\n",
    "As a simple starting point, lets traverse three hops out from each chunk and textualize the different relationships we pick up.  We will use something called a quantified path pattern to accomplish in this. "
   ],
   "id": "2b2ee3da2339365f"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:52:24.007865Z",
     "start_time": "2024-10-04T03:52:23.753886Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorCypherRetriever\n",
    "\n",
    "vc_retriever=VectorCypherRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    retrieval_query=\"\"\"\n",
    "MATCH(node)<-[:FROM_CHUNK]-()-[rl:!FROM_CHUNK]-{1,3}()\n",
    "UNWIND rl AS r\n",
    "WITH DISTINCT r\n",
    "MATCH (n)-[r]->(m)\n",
    "// return textualize relations\n",
    "RETURN n.name + '(' + coalesce(n.details, '') + ')'+ \n",
    "    ' - ' + type(r) + '(' + coalesce(r.details, '') + ')' +  ' -> ' + \n",
    "    m.name + '(' + coalesce(m.details, '') + ')' AS fact\n",
    "        \"\"\",\n",
    ")\n"
   ],
   "id": "caf84995e4bc8d4",
   "outputs": [],
   "execution_count": 17
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:52:24.823778Z",
     "start_time": "2024-10-04T03:52:24.275467Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vc_res = vc_retriever.get_search_results(query_text = \"Which biomarkers are associated with predicting organ damage in lupus patients?\")\n",
    "for i in vc_res.records: print(\"====\\n\" + i.data()['fact']) "
   ],
   "id": "4a1df583f2450f35",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - ASSOCIATED_WITH(Lupus is associated with neuropsychiatric involvement.) -> neuropsychiatric involvement(The impact of lupus on neurological and psychiatric health.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - ASSOCIATED_WITH(Lupus is associated with renal involvement.) -> renal involvement(The impact of lupus on kidney function.)\n",
      "====\n",
      "BILAG score(A scoring system used to assess disease activity in patients.) - ASSOCIATED_WITH(BILAG score is associated with renal involvement.) -> renal involvement(The impact of lupus on kidney function.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - ASSOCIATED_WITH(Flares in lupus are probably linked to epigenetic dis-equilibrium.) -> epigenetic dis-equilibrium(A disruption in the normal epigenetic regulation of gene expression.)\n",
      "====\n",
      "epigenetic dis-equilibrium(A disruption in the normal epigenetic regulation of gene expression.) - INCLUDES(DNA methylation is a process involved in epigenetic dis-equilibrium.) -> DNA methylation(A biochemical process involving the addition of a methyl group to the DNA molecule.)\n",
      "====\n",
      "DNA methylation(A biochemical process involving the addition of a methyl group to the DNA molecule.) - AFFECTS(DNA methylation affects the condition of lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "DNA methylation(A biochemical process involving the addition of a methyl group to the DNA molecule.) - AFFECTS(DNA methylation has been found to affect type 1 interferon genes.) -> type 1 interferon genes(Genes that encode proteins involved in the immune response.)\n",
      "====\n",
      "DNA methylation(A biochemical process involving the addition of a methyl group to the DNA molecule.) - AFFECTS(DNA methylation has been found to affect MHC genes.) -> MHC genes(Genes that encode major histocompatibility complex proteins important for immune system function.)\n",
      "====\n",
      "DNA methylation(A biochemical process involving the addition of a methyl group to the DNA molecule.) - AFFECTS(DNA methylation has been found to affect IL-2.) -> IL-2(A cytokine that plays a central role in the immune response.)\n",
      "====\n",
      "DNA methylation(A biochemical process involving the addition of a methyl group to the DNA molecule.) - AFFECTS(DNA methylation has been found to affect FOXP3.) -> FOXP3(A transcription factor crucial for the development and function of regulatory T cells.)\n",
      "====\n",
      "MicroRNAs(Small non-coding RNA molecules that regulate gene expression.) - INTERACTS_WITH(MicroRNAs are linked to DNA methylation.) -> DNA methylation(A biochemical process involving the addition of a methyl group to the DNA molecule.)\n",
      "====\n",
      "Epstein-Barr Virus(Viraemia occurs in lupus patients.) - ASSOCIATED_WITH(Epstein-Barr Virus is associated with lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "Epstein-Barr Virus(Viraemia occurs in lupus patients.) - INDUCES(Epstein-Barr Virus induces the proliferation of B cells.) -> B cells(A type of white blood cell that produces antibodies.)\n",
      "====\n",
      "B cells(A type of white blood cell that produces antibodies.) - PRODUCES(B cells produce autoantibodies intrarenally.) -> intrarenal production of autoantibodies(The production of antibodies within the kidney that target the body's own tissues.)\n",
      "====\n",
      "oxidative stress(An imbalance between free radicals and antioxidants in the body.) - HAS_EFFECT(Oxidative stress may stimulate the proliferation of B cells.) -> B cells(A type of white blood cell that produces antibodies.)\n",
      "====\n",
      "B cells(A type of white blood cell that produces antibodies.) - ACTIVATES(B cells undergo somatic hypermutation.) -> somatic hypermutation(A process that increases the diversity of antibodies.)\n",
      "====\n",
      "B cells(A type of white blood cell that produces antibodies.) - ACTIVATES(B cells undergo clonal expansion.) -> clonal expansion(The process by which a specific immune cell proliferates in response to an antigen.)\n",
      "====\n",
      "Epstein-Barr Virus(Viraemia occurs in lupus patients.) - OBSERVED_IN(Epstein-Barr Virus viraemia occurs in lupus patients.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "Steroids(A class of drugs used to reduce inflammation.) - USED_FOR(Steroids are used to treat lupus.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "Immunosuppressives(Drugs that suppress or reduce the strength of the body’s immune system.) - USED_FOR(Immunosuppressives are used for the treatment of lupus.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "Hydroxychloroquine(A medication used to prevent and treat malaria and to treat certain autoimmune diseases.) - USED_FOR(Hydroxychloroquine is used for the treatment of lupus.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "Prednisolone(A corticosteroid medication used in the treatment of lupus.) - USED_FOR(Prednisolone is used for the treatment of lupus.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "Lupus(A chronic autoimmune disease that can affect various parts of the body.) - INTERACTS_WITH(Lupus is proposed to interact at the epigenetic level.) -> Hypo-acetylation(A process associated with active chromatin.)\n",
      "====\n",
      "Vitamin D associations(Extensive associations with vitamin D correlating serum levels and vitamin D-receptor genomic binding sites.) - CORRELATES_WITH(Vitamin D associations correlate with lupus.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "BSR guideline on SLE(Guidelines adapted for the management of systemic lupus erythematosus.) - DESCRIBES(The BSR guideline on SLE describes the management of lupus.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "Immunological changes in lupus(A review capturing major immunological changes linked to the pathophysiology of lupus.) - DISCUSSES(The paper discusses the challenges presented by lupus.) -> Lupus(A chronic autoimmune disease that can affect various parts of the body.)\n",
      "====\n",
      "Belimumab(A drug used in the treatment of systemic lupus erythematosus.) - TREATMENT_FOR(Belimumab is used as a treatment for lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "Belimumab(A drug used in the treatment of systemic lupus erythematosus.) - ASSOCIATED_WITH(Belimumab is associated with high SLEDAI score.) -> SLEDAI score(A score used to assess the disease activity in systemic lupus erythematosus.)\n",
      "====\n",
      "Systemic Lupus Erythematosus(A chronic autoimmune disease that can affect various parts of the body.) - HAS_SYMPTOM(The SLEDAI score is used to assess symptoms of systemic lupus erythematosus.) -> SLEDAI score(A score used to assess the disease activity in systemic lupus erythematosus.)\n",
      "====\n",
      "Belimumab(A drug used in the treatment of systemic lupus erythematosus.) - ASSOCIATED_WITH(Belimumab can cause side-effects.) -> side-effects(Adverse effects caused by medications.)\n",
      "====\n",
      "Rituximab(A medication used to treat certain autoimmune diseases, including lupus.) - ASSOCIATED_WITH(Rituximab can cause side-effects.) -> side-effects(Adverse effects caused by medications.)\n",
      "====\n",
      "Belimumab(A drug used in the treatment of systemic lupus erythematosus.) - ASSOCIATED_WITH(Belimumab is associated with polyarthritis.) -> polyarthritis(A condition characterized by inflammation in multiple joints.)\n",
      "====\n",
      "Belimumab(A drug used in the treatment of systemic lupus erythematosus.) - TREATMENT_FOR(Belimumab is used as a treatment for refractory systemic lupus erythematosus.) -> Refractory systemic lupus erythematosus(A severe form of systemic lupus erythematosus that does not respond to standard treatments.)\n",
      "====\n",
      "Belimumab(A drug used in the treatment of systemic lupus erythematosus.) - USED_FOR(Belimumab is used for the treatment of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(Epigenetic aspects are associated with SLE.) -> Epigenetic(Epigenetic aspects are considered in the context of SLE.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(Microbiome aspects are associated with SLE.) -> Microbiome(Microbiome aspects are considered in the context of SLE.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(Environmental aspects are associated with SLE.) -> Environmental aspects(Environmental aspects are considered in the context of SLE.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(SLE pathogenesis involves an imbalance in apoptosis.) -> apoptosis(The process of programmed cell death.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(SLE patients have an abnormal subset of neutrophils.) -> neutrophils(A type of white blood cell that plays a role in the immune response.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(SLE is associated with defects in T cell signalling.) -> T cells(A type of immune cell.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(Increased population of plasmacytoid DC in SLE patients.) -> plasmacytoid DC(A type of dendritic cell that produces type 1 interferon.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(Reduced population of conventional DC in SLE promotes auto-reactivity.) -> conventional DC(A type of dendritic cell that promotes self-tolerance.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(C2 and C4 are complement protein deficits linked to SLE.) -> C2(A complement protein associated with immune response.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(C2 and C4 are complement protein deficits linked to SLE.) -> C4(A complement protein involved in the immune system.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - ASSOCIATED_WITH(SLE and Sjogren's syndrome are both autoimmune conditions.) -> Sjogrens(Sjogren's syndrome, an autoimmune disease characterized by dry eyes and mouth.)\n",
      "====\n",
      "Complement proteins(Proteins that play a role in the immune system.) - ASSOCIATED_WITH(Complement protein deficits are linked to SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "C2(A complement protein linked to SLE.) - ASSOCIATED_WITH(C2 is a complement protein linked to SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "C4(A complement protein linked to SLE.) - ASSOCIATED_WITH(C4 is a complement protein linked to SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "B cells(B cells are responsible for antigen response, regulation of other cells, antibody and cytokine production.) - ASSOCIATED_WITH(B cells have a central role in SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "HLA(Human leukocyte antigen, associated with SLE.) - ASSOCIATED_WITH(HLA is associated with SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "DRB1(Locus encoding part of the MHC class II proteins.) - ASSOCIATED_WITH(DRB1 is associated with SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "BQA1(Locus encoding part of the MHC class II proteins.) - ASSOCIATED_WITH(BQA1 is associated with SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Renal lupus(A condition that can be active without other SLE disease involvement.) - ASSOCIATED_WITH(Renal lupus can be active without other SLE disease involvement.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Cerebral lupus(A condition scored in 20 separate sections from seizures to demyelination.) - ASSOCIATED_WITH(Cerebral lupus is a manifestation of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "belimumab(Belimumab is a drug that targets B cells through BLyS/BAFF blockage.) - TREATMENT_FOR(Belimumab is known to be an effective treatment for SLE patients.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "rituximab(Rituximab is a drug used for B cell depletion.) - TREATMENT_FOR(Rituximab is known to be an effective treatment for SLE patients.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Benlysta(Belimumab, a medication used to treat lupus.) - TREATMENT_FOR(Benlysta is approved for the treatment of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - INVOLVES(Several immune system cells are thought to be involved in SLE pathogenesis.) -> immune system cells(Cells that are part of the immune system and are involved in the body's defense mechanisms.)\n",
      "====\n",
      "Precision medicine(A tailored approach to medical treatment based on individual characteristics.) - ASSESSES(Precision medicine assesses SLE patients.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Current treatment approach(The current treatment approach for SLE is addressed.) - ASSESSES(The current treatment approach assesses SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - EXPRESSES(Active SLE patients develop a higher number of TLR9 expressing B-cells.) -> B-cells(A type of white blood cell that plays a role in the immune response.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - EXPRESSES(Active SLE patients develop a higher number of TLR9 expressing macrophages.) -> macrophages(A type of immune cell that engulfs and digests cellular debris and pathogens.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - PARTICIPATES_IN(The complement system participates in SLE.) -> complement system(A part of the immune system that enhances the ability to clear microbes.)\n",
      "====\n",
      "Innate Immune System(The body's first line of defense against pathogens, providing immediate but non-specific responses.) - PARTICIPATES_IN(The innate immune system participates in the condition of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Complement System(A part of the immune system that enhances the ability to clear microbes and damaged cells.) - PARTICIPATES_IN(The complement system participates in SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Microparticles(Small membrane vesicles circulating in blood, that detach from apoptotic cells.) - LINKED_TO(Differences in microparticles have been noticed compared to SLE patients.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Complement Consumption(A marker for SLE activity.) - HAS_EFFECT(Complement consumption is a marker for SLE activity.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - AFFECTS(SLE primarily affects women.) -> Women(A demographic group primarily affected by SLE, with a prevalence of 90% during childbearing years.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - AFFECTS(SLE is more prevalent in non-white populations.) -> Non-white populations(A demographic group that is more prevalent in SLE cases.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - AFFECTS(SLE affects the regulation of B-cells.) -> B-cells(A type of white blood cell that plays a role in the immune response.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - AFFECTS(SLE affects B cell regulation.) -> B cell regulation(B cell regulation is impaired in SLE patients.)\n",
      "====\n",
      "ultraviolet light(A type of electromagnetic radiation that can cause skin damage.) - AFFECTS(Ultraviolet light exposure is a known risk factor for SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "toxins(Substances that can cause harm to biological systems.) - AFFECTS(Toxin exposure is a known risk factor for SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "infections(Invasion of the body by pathogens.) - AFFECTS(Infections are a known risk factor for SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "gut microbiota(The community of microorganisms residing in the gastrointestinal tract.) - AFFECTS(Differential gut microbiota has been found in SLE patients.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - HAS_SYMPTOM(Impaired regulation is a symptom of SLE.) -> impaired regulation(The dysfunction in the regulation of SLE B-cells.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - HAS_SYMPTOM(Altered activation status is a symptom of SLE.) -> altered activation status(Changes in the baseline activation status of SLE B-cells.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - HAS_SYMPTOM(Increased auto-reactivity is a symptom of SLE.) -> increased auto-reactivity(Higher tendency of early immature B cells to react against self-antigens.)\n",
      "====\n",
      "Atacicept(A drug being evaluated for the treatment of systemic lupus erythematosus.) - USED_FOR(Atacicept is used for the treatment of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "antimalarials(Medications used to treat malaria, beneficial in SLE patients.) - USED_FOR(Antimalarials are used for the treatment of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "glucocorticoids(A class of corticosteroids used in the treatment of SLE.) - USED_FOR(Glucocorticoids are used for the treatment of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "immunosuppressants(Drugs that suppress or reduce the strength of the body's immune system.) - USED_FOR(Immunosuppressants are used for the treatment of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "prednisone(A corticosteroid medication used to treat various conditions.) - USED_FOR(Prednisone is used for treating SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "Anifrolumab(A drug that blocks interferon α.) - USED_FOR(Anifrolumab is used for the treatment of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - INDUCES(SLE serum IgG can induce aberrant T cell receptor signalling.) -> T cell receptor signalling(A process that activates T cells upon recognition of antigens.)\n",
      "====\n",
      "SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.) - RESULTS_IN(Treatment of SLE aims for remission.) -> remission(A decrease in or disappearance of signs and symptoms of SLE.)\n",
      "====\n",
      "Precision in lupus care(There is scope towards improving precision in lupus care.) - RESULTS_IN(Improving precision in lupus care results in better management of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "SLEDAI scoring systems(Scoring systems that are limited in representation of lupus features.) - DESCRIBES(SLEDAI scoring systems describe features of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "TLR9(Toll-like receptor involved in the immune response.) - ACTIVATES(TLR9 is activated in the context of SLE.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "early immature B cells(A developmental stage of B cells that shows increased auto-reactivity in SLE patients.) - PART_OF(Early immature B cells are part of the SLE condition.) -> SLE(SLE is characterized by loss of self-immune tolerance, production of self-reacting antibodies and formation of immune complexes that precipitate in tissues, causing chronic systemic inflammation and organ damage.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - USES(Lupus care involves the use of Belimumab.) -> Belimumab(A drug used in the treatment of systemic lupus erythematosus.)\n",
      "====\n",
      "rituximab(Rituximab is a drug used for B cell depletion.) - TREATMENT_FOR(Rituximab is used as a treatment for lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "cyclophosphamide(A second-line treatment used to induce remission.) - TREATMENT_FOR(Cyclophosphamide is used to treat lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - INVOLVES(Lupus care involves managing autoimmunity.) -> autoimmunity(A process where the immune system attacks the body's own cells.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - MANIFESTS_AS(Lupus manifests as diverse clinical features.) -> diverse clinical features(The various clinical manifestations of lupus.)\n",
      "====\n",
      "initial evaluation(An assessment to profile the disease and its impact.) - ASSESSES(The initial evaluation assesses the condition of lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.) - ASSESSES(The British Isles Lupus Assessment Group assesses patients with lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "molecular diagnostics(Diagnostics used to guide treatment throughout the patient timecourse.) - INCLUDES(Molecular diagnostics are included in the care for lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "biomarkers(Biological indicators used to assess disease risk and progression.) - EXPRESSES(Biomarkers express the condition of lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "individuals(Refers to people in different health states: active, inactive, and healthy.) - PARTICIPATES_IN(Individuals participate in the study of lupus in various health states.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "flare prediction(The ability to predict exacerbations of the disease.) - HAS_EFFECT(Flare prediction has an effect on the condition of lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - AFFECTS(Lupus affects mortality figures.) -> mortality figures(Statistics that indicate the number of deaths in a given population.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - AFFECTS(Lupus affects organ selectivity.) -> organ selectivity(The network of factors that drives organ selectivity in lupus.)\n",
      "====\n",
      "oestrogen receptor(A protein that mediates the effects of estrogen.) - AFFECTS(Oestrogen receptor deficiency reduces activity in lupus-prone mice.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - HAS_SYMPTOM(Lupus manifests as differentially expressed states in individuals.) -> differentially expressed(Variations in the expression levels of genes in different conditions or states.)\n",
      "====\n",
      "adequate treatment(Treatment options that are most suitable for managing the disease.) - USED_FOR(Adequate treatment is used for managing the condition of lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "Cyclophosphamide(has been shown to increase DNA methylation through induction of DNMT1, although its main action is through alkylation and cell cycle arrest) - USED_FOR(Cyclophosphamide is used for treating lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "current treatment(The existing treatment approaches for lupus.) - USED_FOR(Current treatment is used for managing lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "main pathophysiologic pathway(The primary biological pathway involved in the disease.) - INDUCES(The main pathophysiologic pathway induces the condition of lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "TLR4(Toll-like receptor 4, a protein that plays a role in the immune system.) - INDUCES(Overexpression of TLR4 in a mouse model leads to the development of lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "Septrin(A drug that can trigger lupus.) - TRIGGERS(Septrin can trigger lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "tetracyclines(A class of antibiotics that can trigger lupus.) - TRIGGERS(Tetracyclines can trigger lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "penicillins(A class of antibiotics that can trigger lupus.) - TRIGGERS(Penicillins can trigger lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "differential methylation(Variations in DNA methylation patterns that can influence gene expression.) - CAUSES(Differential methylation causes organ selectivity in lupus.) -> lupus(A disease characterized by inflammation and damage to various organs.)\n",
      "====\n",
      "lupus(A disease characterized by inflammation and damage to various organs.) - USES(Lupus care involves the use of Rituximab.) -> Rituximab(A medication used to treat certain autoimmune diseases, including lupus.)\n",
      "====\n",
      "Belimumab(A drug used in the treatment of systemic lupus erythematosus.) - REGULATED_BY(Belimumab is allowed for use by NICE.) -> National Institute of Clinical Excellence (NICE)(An organization in the UK that provides guidance on health care.)\n",
      "====\n",
      "National Institute of Clinical Excellence (NICE)(An organization in the UK that provides guidance on health care.) - LOCATED_IN(NICE operates in the UK.) -> UK(A country where specific guidelines for lupus treatment are applied.)\n",
      "====\n",
      "rituximab(Rituximab is a drug used for B cell depletion.) - ASSOCIATED_WITH(Rituximab's response is distinguished by the interferon signature.) -> interferon signature(A set of gene expression patterns associated with interferon response.)\n",
      "====\n",
      "BAFF(A cytokine involved in B cell development and function.) - ASSOCIATED_WITH(BAFF is associated with the interferon signature.) -> interferon signature(A set of gene expression patterns associated with interferon response.)\n",
      "====\n",
      "APRIL(A cytokine that plays a role in B cell survival and differentiation.) - ASSOCIATED_WITH(APRIL is associated with the interferon signature.) -> interferon signature(A set of gene expression patterns associated with interferon response.)\n",
      "====\n",
      "Signature A(One of the two signatures identified by Vital and colleagues.) - RELATED_TO(Signature A is related to the interferon signature.) -> interferon signature(A set of gene expression patterns associated with interferon response.)\n",
      "====\n",
      "Signature B(A set of nonclassical interferon genes better at predicting response.) - RELATED_TO(Signature B is related to the interferon signature.) -> interferon signature(A set of gene expression patterns associated with interferon response.)\n",
      "====\n",
      "rituximab(Rituximab is a drug used for B cell depletion.) - TREATMENT_FOR(Rituximab is used as a second-line treatment to induce remission for BILAG A disease.) -> BILAG A(A severe disease that implies high dose steroid treatment.)\n",
      "====\n",
      "steroid(A medication used in high doses (≥20mg/day) for treatment.) - TREATMENT_FOR(Steroid is used as a treatment for BILAG A disease.) -> BILAG A(A severe disease that implies high dose steroid treatment.)\n",
      "====\n",
      "immunosuppressive agents(Agents used to suppress the immune response.) - TREATMENT_FOR(Immunosuppressive agents are used as treatment for BILAG A disease.) -> BILAG A(A severe disease that implies high dose steroid treatment.)\n",
      "====\n",
      "anticoagulation therapy(A treatment to prevent blood clots.) - TREATMENT_FOR(Anticoagulation therapy is used for patients with antiphospholipid syndrome.) -> BILAG A(A severe disease that implies high dose steroid treatment.)\n",
      "====\n",
      "antiplatelet therapy(A treatment to prevent platelets from clumping together.) - TREATMENT_FOR(Antiplatelet therapy is used for patients with antiphospholipid syndrome.) -> BILAG A(A severe disease that implies high dose steroid treatment.)\n",
      "====\n",
      "cyclophosphamide(A second-line treatment used to induce remission.) - TREATMENT_FOR(Cyclophosphamide is used as a second-line treatment to induce remission for BILAG A disease.) -> BILAG A(A severe disease that implies high dose steroid treatment.)\n",
      "====\n",
      "rituximab(Rituximab is a drug used for B cell depletion.) - USED_FOR(Rituximab is used to treat severe cutaneous lupus.) -> severe cutaneous lupus(A severe form of lupus that affects the skin.)\n",
      "====\n",
      "severe cutaneous lupus(A severe form of lupus that affects the skin.) - ASSOCIATED_WITH(Severe cutaneous lupus is associated with subcutaneous lupus.) -> subcutaneous lupus(A form of lupus that occurs under the skin.)\n",
      "====\n",
      "initial evaluation(An assessment to profile the disease and its impact.) - INCLUDES(The evaluation includes understanding the pathological processes.) -> pathological processes(Processes that lead to disease development and progression.)\n",
      "====\n",
      "pathological processes(Processes that lead to disease development and progression.) - RESULTS_IN(Pathological processes can lead to specific organ damage.) -> specific organ damage(Damage that occurs to specific organs as a result of disease.)\n",
      "====\n",
      "BSR guideline on SLE(Guidelines adapted for the management of systemic lupus erythematosus.) - AUTHORED(The BSR guideline on SLE was authored by the British Isles Lupus Assessment Group.) -> British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.)\n",
      "====\n",
      "British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.) - INCLUDES(The BILAG scoring system includes assessment of active disease.) -> active disease(Current state of disease activity in lupus patients.)\n",
      "====\n",
      "British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.) - INCLUDES(The BILAG scoring system includes assessment of previous damage.) -> previous damage(Damage caused by previous disease activity or treatment.)\n",
      "====\n",
      "British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.) - INCLUDES(The BILAG scoring system includes assessment of complications of therapy.) -> complications of therapy(Adverse effects resulting from treatment of lupus.)\n",
      "====\n",
      "British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.) - CLASSIFIES(The BILAG scoring system classifies lupus as mild disease.) -> mild disease(Classification of lupus indicating less severe symptoms.)\n",
      "====\n",
      "British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.) - CLASSIFIES(The BILAG scoring system classifies lupus as moderate disease.) -> moderate disease(Classification of lupus indicating moderate severity of symptoms.)\n",
      "====\n",
      "British Isles Lupus Assessment Group(Group that developed the BILAG scoring system for lupus management.) - CLASSIFIES(The BILAG scoring system classifies lupus as severe disease.) -> severe disease(Classification of lupus indicating severe symptoms.)\n",
      "====\n",
      "mortality figures(Statistics that indicate the number of deaths in a given population.) - RESULTS_IN(Mortality figures have improved from 50% 4-year survival.) -> 4-year survival(The percentage of patients who are alive four years after diagnosis.)\n",
      "====\n",
      "mortality figures(Statistics that indicate the number of deaths in a given population.) - RESULTS_IN(Mortality figures have improved to approximately 90% 10-year survival.) -> 10-year survival(The percentage of patients who are alive ten years after diagnosis.)\n",
      "====\n",
      "FOXP3(A transcription factor crucial for the development and function of regulatory T cells.) - PARTICIPATES_IN(FOXP3 is crucial for the development and function of regulatory T cells.) -> regulatory T cells(A type of immune cell that helps control the immune response.)\n",
      "====\n",
      "MicroRNAs(Small non-coding RNA molecules that regulate gene expression.) - INDUCES(MicroRNAs are mechanistically linked to de novo methylation.) -> de novo methylation(The process of methylation occurring for the first time at a specific site in the DNA.)\n",
      "====\n",
      "oestrogen receptor(A protein that mediates the effects of estrogen.) - REDUCES(Oestrogen receptor deficiency impairs TLR4 signaling.) -> TLR4(Toll-like receptor 4, a protein that plays a role in the immune system.)\n",
      "====\n",
      "Cyclophosphamide(has been shown to increase DNA methylation through induction of DNMT1, although its main action is through alkylation and cell cycle arrest) - ASSOCIATED_WITH(Cyclophosphamide is mentioned in the article regarding its effects) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Dove Press(A publishing organization.) - AUTHORED(Dove Press published the article.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Lever et al(Authors of the paper.) - AUTHORED(Lever et al authored the paper in the journal.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Lever(An author of the published work.) - AUTHORED(Lever is one of the authors of the article.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(A journal article published in 2020.) - PUBLISHED_IN(The article is published in the journal.) -> Pharmacogenomics and Personalized Medicine(The journal in which the article was published.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(A journal article published in 2020.) - PUBLISHED_IN(The journal Pharmacogenomics and Personalized Medicine is published by Dove Press.) -> Dove Press(A publisher of scientific journals.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(A journal article published in 2020.) - PUBLISHED_IN(the article is published by Dove Press) -> Dove Press(A publishing organization.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(A journal article published in 2020.) - ASSOCIATED_WITH(The article discusses pharmacogenomics.) -> Pharmacogenomics(A field of study that examines how genes affect a person's response to drugs.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(A journal article published in 2020.) - ASSOCIATED_WITH(The article discusses personalized medicine.) -> Personalized Medicine(A medical model that proposes the customization of healthcare.)\n",
      "====\n",
      "mTOR(a key player in T cell survival, proliferation and activation) - ASSOCIATED_WITH(mTOR is discussed in the context of T cell survival in the article) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(A journal article published in 2020.) - ASSESSES(The article can be submitted through the website.) -> www.dovepress.com(Website for submitting manuscripts.)\n",
      "====\n",
      "Plasma exchange(A procedure that removes and replaces blood plasma.) - ASSESSES(Plasma exchange is assessed for its effectiveness in treatment.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Hydroxychloroquine(A medication used to prevent and treat malaria and to treat certain autoimmune diseases.) - USED_FOR(Hydroxychloroquine is used to treat autoimmune diseases.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Cyclophosphamide(has been shown to increase DNA methylation through induction of DNMT1, although its main action is through alkylation and cell cycle arrest) - USED_FOR(Cyclophosphamide is used to treat various types of cancer.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Methotrexate(A medication used to treat certain types of cancer and autoimmune diseases) - USED_FOR(Methotrexate is used as a chemotherapy agent.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Corticosteroids(A class of drugs used to treat various conditions by suppressing inflammation.) - USED_FOR(Corticosteroids are used to treat various conditions.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Azathioprine(An immunosuppressive medication used to prevent organ rejection.) - USED_FOR(Azathioprine is used to prevent organ rejection.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Mycophenolate(An immunosuppressive drug used to prevent organ rejection.) - USED_FOR(Mycophenolate is used to prevent organ rejection.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "Low molecular weight heparin(An anticoagulant used to prevent and treat blood clots.) - USED_FOR(Low molecular weight heparin is used to prevent blood clots.) -> Pharmacogenomics and Personalized Medicine(A journal article published in 2020.)\n",
      "====\n",
      "black lupus patients(A demographic group of patients diagnosed with lupus who are of African descent.) - CORRELATES_WITH(Black lupus patients do not respond as well to Cyclophosphamide.) -> Cyclophosphamide(has been shown to increase DNA methylation through induction of DNMT1, although its main action is through alkylation and cell cycle arrest)\n",
      "====\n",
      "Caucasians(A demographic group of patients diagnosed with lupus who are of European descent.) - CORRELATES_WITH(Caucasians respond better to Cyclophosphamide compared to black lupus patients.) -> Cyclophosphamide(has been shown to increase DNA methylation through induction of DNMT1, although its main action is through alkylation and cell cycle arrest)\n",
      "====\n",
      "NHS England(The National Health Service in England.) - ASSOCIATED_WITH(NHS England permits the use of Rituximab.) -> Rituximab(A medication used to treat certain autoimmune diseases, including lupus.)\n",
      "====\n",
      "Rituximab(A medication used to treat certain autoimmune diseases, including lupus.) - TREATMENT_FOR(Rituximab is used to treat renal lupus.) -> renal lupus(A form of lupus that affects the kidneys.)\n",
      "====\n",
      "costimulation(A necessary second signal for T cell activation.) - ASSOCIATED_WITH(Costimulation is essential in the renal lupus pathogenic network.) -> renal lupus(A form of lupus that affects the kidneys.)\n",
      "====\n",
      "renal lupus(A form of lupus that affects the kidneys.) - HAS_SYMPTOM(Renal lupus often presents with haematological problems.) -> haematological problems(Issues related to the blood, such as thrombocytopenia or haemolytic anaemia.)\n",
      "====\n",
      "renal lupus(A form of lupus that affects the kidneys.) - HAS_SYMPTOM(Renal lupus can lead to renal disease.) -> renal disease(A disease affecting the kidneys.)\n",
      "====\n",
      "renal lupus(A form of lupus that affects the kidneys.) - PART_OF(Renal lupus can be active without other SLE disease involvement.) -> active disease(A state of disease characterized by increased activity.)\n",
      "====\n",
      "Lupus APS(Antiphospholipid syndrome associated with lupus.) - TREATMENT_FOR(Rituximab is used to treat Lupus APS.) -> Rituximab(A medication used to treat certain autoimmune diseases, including lupus.)\n",
      "====\n",
      "Mononeuritis Multiplex(A neurological condition that affects multiple nerves.) - TREATMENT_FOR(Rituximab is used to treat Mononeuritis Multiplex.) -> Rituximab(A medication used to treat certain autoimmune diseases, including lupus.)\n",
      "====\n",
      "American College of Rheumatology(An organization that developed revised criteria in 1997.) - RECOMMENDS(The American College of Rheumatology recommends the use of Rituximab in renal lupus.) -> Rituximab(A medication used to treat certain autoimmune diseases, including lupus.)\n",
      "====\n",
      "American College of Rheumatology(An organization that developed revised criteria in 1997.) - DEVELOPED(American College of Rheumatology developed revised criteria in 1997.) -> classification criteria(A set of criteria developed for the classification of systemic lupus erythematosus.)\n",
      "====\n",
      "European League Against Rheumatism(An organization focused on rheumatology research and education.) - RECOMMENDS(The European League Against Rheumatism recommends the use of Rituximab in renal lupus.) -> Rituximab(A medication used to treat certain autoimmune diseases, including lupus.)\n",
      "====\n",
      "Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus(A study discussing the role of autoantibodies in predicting neuropsychiatric events in systemic lupus erythematosus.) - AUTHORED() -> Hanly J(An author of the first paper.)\n",
      "====\n",
      "Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus(A study discussing the role of autoantibodies in predicting neuropsychiatric events in systemic lupus erythematosus.) - AUTHORED() -> Urowitz MB(An author of the first paper.)\n",
      "====\n",
      "Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus(A study discussing the role of autoantibodies in predicting neuropsychiatric events in systemic lupus erythematosus.) - AUTHORED() -> Su L(An author of the first paper.)\n",
      "====\n",
      "Neurological disease in lupus: toward a personalized medicine approach(A paper focusing on neurological diseases in lupus and the approach towards personalized medicine.) - AUTHORED() -> McGlasson S(An author of the second paper.)\n",
      "====\n",
      "Neurological disease in lupus: toward a personalized medicine approach(A paper focusing on neurological diseases in lupus and the approach towards personalized medicine.) - AUTHORED() -> Wiseman S(An author of the second paper.)\n",
      "====\n",
      "Neurological disease in lupus: toward a personalized medicine approach(A paper focusing on neurological diseases in lupus and the approach towards personalized medicine.) - AUTHORED() -> Wardlaw J(An author of the second paper.)\n",
      "====\n",
      "Neurological disease in lupus: toward a personalized medicine approach(A paper focusing on neurological diseases in lupus and the approach towards personalized medicine.) - AUTHORED() -> Dhaun N(An author of the second paper.)\n",
      "====\n",
      "Neurological disease in lupus: toward a personalized medicine approach(A paper focusing on neurological diseases in lupus and the approach towards personalized medicine.) - AUTHORED() -> Hunt DPJ(An author of the second paper.)\n",
      "====\n",
      "clinician(A medical professional who assesses disease activity.) - ASSESSES(The clinician assesses the activity of the active disease.) -> active disease(A state of disease characterized by increased activity.)\n",
      "====\n",
      "scoring(A method to determine disease activity based on various categories.) - INCLUDES(Scoring includes categories that determine disease activity.) -> active disease(A state of disease characterized by increased activity.)\n",
      "====\n",
      "active disease(A state of disease characterized by increased activity.) - HAS_EFFECT(Active disease is associated with increased anti-dsDNA antibody levels.) -> anti-dsDNA antibody levels(Blood markers that increase with active disease.)\n",
      "====\n",
      "active disease(A state of disease characterized by increased activity.) - HAS_EFFECT(Active disease is associated with decreased C3 levels.) -> C3 levels(Blood markers that fall when the disease is active.)\n",
      "====\n",
      "The immune cell landscape in kidneys of patients with lupus nephritis(A research paper discussing the immune cell landscape in lupus nephritis.) - CITES(The first paper cites the second paper.) -> Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis(A research paper exploring the roles of anti-dsDNA antibodies and renal cells in lupus nephritis.)\n",
      "====\n",
      "Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis(A research paper exploring the roles of anti-dsDNA antibodies and renal cells in lupus nephritis.) - ASSOCIATED_WITH(The second paper discusses aspects related to lupus nephritis.) -> Lupus nephritis(A condition characterized by inflammation of the kidneys due to systemic lupus erythematosus.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - PUBLISHED_IN(The journal is published by Dove Press.) -> Dove Press(A publishing organization.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - PUBLISHED_IN() -> Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus(A research article discussing predictors of treatment outcomes in lupus.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - PUBLISHED_IN() -> Prediction of response to rituximab in SLE using a validated two-score system for interferon status(A research article discussing prediction of treatment response in lupus.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - PUBLISHED_IN(Research related to anti-dsDNA published in the journal.) -> Anti-dsDNA(An antibody believed to relate to disease activity.)\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(This article discusses precision medicine in the context of systemic lupus erythematosus.) - PUBLISHED_IN(The article was published in this journal.) -> Pharmacogenomics and Personalized Medicine(The journal in which the article was published.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - ASSOCIATED_WITH(The journal characterizes the influence of genotype on pharmacology.) -> Pharmacogenomics(The study of how genes affect a person's response to drugs.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - LINKED_TO(The journal is indexed by the American Chemical Society's Chemical Abstracts Service.) -> American Chemical Society(An organization that indexes the journal in its Chemical Abstracts Service.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) - PUBLISHED_BY(Dove Press publishes the journal.) -> Dove Press(A publishing organization.)\n",
      "====\n",
      "Neuropsychiatric lupus: new mechanistic insights and future treatment directions(A paper authored by Schwartz N, Stock AD, Putterman C published in Nat Rev Rheumatol in 2019.) - PUBLISHED_IN(The paper is associated with Dove Press.) -> Dove Press(A publishing organization.)\n",
      "====\n",
      "Neuropsychiatric lupus: new mechanistic insights and future treatment directions(A paper authored by Schwartz N, Stock AD, Putterman C published in Nat Rev Rheumatol in 2019.) - AUTHORED(The paper 'Neuropsychiatric lupus: new mechanistic insights and future treatment directions' is published in Nat Rev Rheumatol.) -> Nat Rev Rheumatol(A journal publication.)\n",
      "====\n",
      "Neuropsychiatric lupus: new mechanistic insights and future treatment directions(A paper authored by Schwartz N, Stock AD, Putterman C published in Nat Rev Rheumatol in 2019.) - PUBLISHED_IN(The paper is published in the journal Nat Rev Rheumatol.) -> Nat Rev Rheumatol(A journal publication.)\n",
      "====\n",
      "Lever et al(Authors of the paper.) - AUTHORED(Lever et al authored the manuscript submitted to Dove press.) -> Dove press(The journal where the manuscript is submitted.)\n",
      "====\n",
      "Parodis I(An author of the research article.) - AUTHORED() -> Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus(A research article discussing predictors of treatment outcomes in lupus.)\n",
      "====\n",
      "Johansson P(An author of the research article.) - AUTHORED() -> Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus(A research article discussing predictors of treatment outcomes in lupus.)\n",
      "====\n",
      "Gomez A(An author of the research article.) - AUTHORED() -> Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus(A research article discussing predictors of treatment outcomes in lupus.)\n",
      "====\n",
      "Soukka S(An author of the research article.) - AUTHORED() -> Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus(A research article discussing predictors of treatment outcomes in lupus.)\n",
      "====\n",
      "Emamikia S(An author of the research article.) - AUTHORED() -> Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus(A research article discussing predictors of treatment outcomes in lupus.)\n",
      "====\n",
      "Chatzidionysiou K(An author of the research article.) - AUTHORED() -> Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus(A research article discussing predictors of treatment outcomes in lupus.)\n",
      "====\n",
      "Prediction of response to rituximab in SLE using a validated two-score system for interferon status(A research article discussing prediction of treatment response in lupus.) - AUTHORED() -> Suttichet TB(One of the authors of the first article.)\n",
      "====\n",
      "Prediction of response to rituximab in SLE using a validated two-score system for interferon status(A research article discussing prediction of treatment response in lupus.) - AUTHORED() -> Kittanamongkolchai W(One of the authors of the first article.)\n",
      "====\n",
      "Prediction of response to rituximab in SLE using a validated two-score system for interferon status(A research article discussing prediction of treatment response in lupus.) - AUTHORED() -> Phromjeen C(One of the authors of the first article.)\n",
      "====\n",
      "Alase A(An author of the research article.) - AUTHORED() -> Prediction of response to rituximab in SLE using a validated two-score system for interferon status(A research article discussing prediction of treatment response in lupus.)\n",
      "====\n",
      "Wigston Z(An author of the research article.) - AUTHORED() -> Prediction of response to rituximab in SLE using a validated two-score system for interferon status(A research article discussing prediction of treatment response in lupus.)\n",
      "====\n",
      "Burska A(An author of the research article.) - AUTHORED() -> Prediction of response to rituximab in SLE using a validated two-score system for interferon status(A research article discussing prediction of treatment response in lupus.)\n",
      "====\n",
      "Anti-dsDNA(An antibody believed to relate to disease activity.) - ASSOCIATED_WITH(Anti-dsDNA antibodies relate to disease activity.) -> Disease activity(The level of disease progression or severity.)\n",
      "====\n",
      "Plasma cell(A type of white blood cell that produces antibodies.) - REDUCES(B-cell depletion reduces the levels of antibodies efficiently.) -> Anti-dsDNA(An antibody believed to relate to disease activity.)\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(This article discusses precision medicine in the context of systemic lupus erythematosus.) - AUTHORED(Elliott Lever is one of the authors of the article.) -> Elliott Lever(One of the authors of the article.)\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(This article discusses precision medicine in the context of systemic lupus erythematosus.) - AUTHORED(Marta R Alves is one of the authors of the article.) -> Marta R Alves(One of the authors of the article.)\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(This article discusses precision medicine in the context of systemic lupus erythematosus.) - AUTHORED(David A Isenberg is one of the authors of the article.) -> David A Isenberg(One of the authors of the article.)\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(This article discusses precision medicine in the context of systemic lupus erythematosus.) - DESCRIBES(The article discusses systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease that affects various parts of the body.)\n",
      "====\n",
      "Pharmacogenomics(The study of how genes affect a person's response to drugs.) - USED_FOR(Pharmacogenomics leads to the development of personalized treatment programs.) -> Personalized treatment programs(Individualized drug selection for improved safety, efficacy, and sustainability.)\n",
      "====\n",
      "Validation of new systemic lupus erythematosus classification criteria(A research paper that discusses the validation of new classification criteria for systemic lupus erythematosus.) - AUTHORED(The article is associated with Dove Press.) -> Dove Press(A publisher of scientific journals.)\n",
      "====\n",
      "Validation of new systemic lupus erythematosus classification criteria(A research paper that discusses the validation of new classification criteria for systemic lupus erythematosus.) - PUBLISHED_IN(The article is published in the Ann Rheum Dis journal.) -> Ann Rheum Dis(A journal that publishes research related to rheumatology.)\n",
      "====\n",
      "Piantoni et al.(A study discussing baseline serum levels of baff or april as predictors of sledai response after treatment with belimumab.) - PUBLISHED_IN(The study by Piantoni et al. is published in Dove Press.) -> Dove Press(A publisher of scientific journals.)\n",
      "====\n",
      "Autoimmun(A publication discussing autoimmune diseases.) - CITES(The Autoimmun article cites the study by Piantoni et al.) -> Piantoni et al.(A study discussing baseline serum levels of baff or april as predictors of sledai response after treatment with belimumab.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine 2020:13 40(An article published in the Dove Press journal.) - PUBLISHED_IN() -> Dove Press(A publisher of scientific journals.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine 2020:13 40(An article published in the Dove Press journal.) - INCLUDES() -> T cells(A type of immune cell.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine 2020:13 40(An article published in the Dove Press journal.) - INCLUDES() -> dendritic cells(A type of immune cell that processes antigen material.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine 2020:13 40(An article published in the Dove Press journal.) - INCLUDES() -> epithelial cells(Cells that line the surfaces of organs and structures.)\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine 2020:13 40(An article published in the Dove Press journal.) - INCLUDES() -> fibroblasts(Cells that produce collagen and other fibers.)\n",
      "====\n",
      "Dove Press(A publisher of scientific journals.) - DESCRIBES(Dove Press describes the disease lupus.) -> Lupus(An autoimmune disease that can affect various organs.)\n",
      "====\n",
      "Lupus(An autoimmune disease that can affect various organs.) - MANIFESTS_AS(Lupus manifests as lupus nephritis.) -> Lupus Nephritis(A condition characterized by inflammation of the kidneys due to lupus.)\n",
      "====\n",
      "Lupus(An autoimmune disease that can affect various organs.) - AFFECTS(Lupus affects the kidney.) -> Kidney(An organ that can be affected by lupus, specifically in lupus nephritis.)\n",
      "====\n",
      "Methotrexate(A medication used to treat certain types of cancer and autoimmune diseases) - USED_WITH(Methotrexate may be used with MMF) -> MMF(Mycophenolate mofetil, an immunosuppressive drug)\n",
      "====\n",
      "Nephritis(An inflammation of the kidneys.) - TREATMENT_FOR(Mycophenolate mofetil is used to treat Nephritis.) -> MMF(Mycophenolate mofetil, an immunosuppressive drug)\n",
      "====\n",
      "MMF(Mycophenolate mofetil, an immunosuppressive drug) - USED_WITH(Mycophenolate mofetil is used in accordance with the guidelines.) -> British Society of Rheumatology Guidelines(Guidelines for the treatment of rheumatological conditions.)\n",
      "====\n",
      "Methylprednisolone(A corticosteroid used in the treatment of SLE.) - USED_WITH(Methylprednisolone may be used with MMF) -> MMF(Mycophenolate mofetil, an immunosuppressive drug)\n",
      "====\n",
      "Prednisolone(A corticosteroid medication used in the treatment of lupus.) - USED_WITH(Prednisolone may be used with Methotrexate) -> Methotrexate(A medication used to treat certain types of cancer and autoimmune diseases)\n",
      "====\n",
      "Mild Disease(Characterized by BILAG C Scores/Single B/SLEDAI ≤6.) - TREATMENT_FOR(Prednisolone is used for treating mild SLE.) -> Prednisolone(A corticosteroid medication used in the treatment of lupus.)\n",
      "====\n",
      "Prednisolone(A corticosteroid medication used in the treatment of lupus.) - USED_WITH(Prednisolone may be used with Methylprednisolone) -> Methylprednisolone(A corticosteroid used in the treatment of SLE.)\n",
      "====\n",
      "Prednisolone(A corticosteroid medication used in the treatment of lupus.) - USED_WITH(Prednisolone may be used with AZA) -> AZA(Azathioprine, an immunosuppressive medication)\n",
      "====\n",
      "Prednisolone(A corticosteroid medication used in the treatment of lupus.) - USED_WITH(Prednisolone may be used with HCQ) -> HCQ(Hydroxychloroquine, a medication used to prevent and treat malaria and autoimmune diseases)\n",
      "====\n",
      "Prednisolone(A corticosteroid medication used in the treatment of lupus.) - USED_WITH(Prednisolone is used in accordance with the guidelines.) -> British Society of Rheumatology Guidelines(Guidelines for the treatment of rheumatological conditions.)\n",
      "====\n",
      "NSAIDs(Non-steroidal anti-inflammatory drugs) - USED_WITH(NSAIDs may be used with Methotrexate) -> Methotrexate(A medication used to treat certain types of cancer and autoimmune diseases)\n",
      "====\n",
      "Mycophenolate(An immunosuppressive drug used to prevent organ rejection.) - USED_FOR(Mycophenolate is used for the treatment of lupus nephritis.) -> Lupus Nephritis(A condition characterized by inflammation of the kidneys due to lupus.)\n",
      "====\n",
      "Lupus Nephritis(A condition characterized by inflammation of the kidneys due to lupus.) - ASSOCIATED_WITH(Lupus nephritis is associated with morbidity and mortality.) -> Morbidity and Mortality(Health outcomes associated with lupus nephritis.)\n",
      "====\n",
      "Study on lupus nephritis(A study involving 110 patients that evaluated predictors of response to induction therapy in lupus nephritis.) - ASSESSES(The study assesses the predictors of response to induction therapy in lupus nephritis.) -> Lupus Nephritis(A condition characterized by inflammation of the kidneys due to lupus.)\n",
      "====\n",
      "Afro-Caribbean patients(A demographic group that is more likely to develop lupus nephritis.) - LINKED_TO(Afro-Caribbean patients are linked to a higher likelihood of developing lupus nephritis.) -> Lupus Nephritis(A condition characterized by inflammation of the kidneys due to lupus.)\n",
      "====\n",
      "Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus(An article discussing new loci for systemic lupus erythematosus.) - PUBLISHED_IN() -> Nat Rev Rheumatol(A journal publication.)\n",
      "====\n",
      "The microbiome in SLE pathogenesis(A research article discussing the role of the microbiome in systemic lupus erythematosus.) - PUBLISHED_IN(The article is published in the journal Nat Rev Rheumatol.) -> Nat Rev Rheumatol(A journal publication.)\n",
      "====\n",
      "Ectopic lymphoid neogenesis in rheumatic autoimmune diseases(A research paper discussing ectopic lymphoid neogenesis in autoimmune diseases.) - PUBLISHED_IN() -> Nat Rev Rheumatol(A journal publication.)\n",
      "====\n",
      "Pathogenesis of neuropsychiatric lupus(An article discussing the pathogenesis of neuropsychiatric lupus.) - PUBLISHED_IN() -> Nat Rev Rheumatol(A journal publication.)\n",
      "====\n",
      "Nat Rev Rheumatol(A journal publication.) - CITES(The journal Nat Rev Rheumatol cites the article.) -> The microbiome in SLE pathogenesis(A research article discussing the role of the microbiome in systemic lupus erythematosus.)\n",
      "====\n",
      "Nat Rev Rheumatol(A journal publication.) - CITES(The journal Nat Rev Rheumatol cites the article on intestinal microbiota and systemic lupus erythematosus.) -> Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus(An article authored by Kim JW, Kwok SK, Choe JY, et al. published in Int J Mol Sci in 2019.)\n",
      "====\n",
      "Nat Rev Rheumatol(A journal publication.) - CITES(The journal Nat Rev Rheumatol cites the article on gut pathobiont and autoimmunity.) -> Translocation of a gut pathobiont drives autoimmunity in mice and humans(An article authored by Manfredo Vieira S, Hiltensperger M, Kumar V, et al. published in Science in 2018.)\n",
      "====\n",
      "Nat Rev Rheumatol(A journal publication.) - CITES(The journal Nat Rev Rheumatol cites the article reference by Mu Q, Zhang H, Liao X, et al.) -> Mu Q, Zhang H, Liao X, et al.(An article reference without a title or publication details.)\n",
      "====\n",
      "BILAG grading(A grading system used to assess the severity of lupus.) - ASSESSES(BILAG grading assists in determining the degree of immunosuppression.) -> immunosuppression(A biological process that reduces the activation or efficacy of the immune system.)\n"
     ]
    }
   ],
   "execution_count": 18
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Different retrievers will return different types of data which may be more informative for your us4e case. in the examples above the vectorRetriever just returned some text chunks, but it wasn't clear if that fully answered the search prompt.  The VectorCypherRetriever returned much more information (using the entites and rels connected to the text chunks) some of those \"rules\" seem like they will be useful.  Lets put these into full GraphRAG pipelines below to understand how they will perform. ",
   "id": "898f1c8b6cd1c1ec"
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "## GraphRAG Pipelines\n",
    " You can construct GraphRAG pipelines VectorCypherRetriever with the `GraphRAG` class.  At minimum you will need to pass the constructor an LLM and a retriever. You can also pass the LLM a custome propmt template, but for now we will just use the default.\n",
    " \n",
    "We construct two retrievers below.  One using vectorRetriever, the other using VectorCypherRetriever.  We will compare the results of each iwth a few questions.  \n",
    "\n",
    "For the LLM we will use OpenAI gpt-4o for both, it as stated previously you can use [.....]"
   ],
   "id": "f2e55b8b3511cf1"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:52:33.708497Z",
     "start_time": "2024-10-04T03:52:33.661512Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.llm import OpenAILLM as LLM\n",
    "from neo4j_graphrag.generation.graphrag import GraphRAG\n",
    "\n",
    "llm = LLM(model_name=\"gpt-4o\",  model_params={\"temperature\": 0})\n",
    "\n",
    "vector_rag = GraphRAG(llm=llm, retriever=vector_retriever)\n",
    "vc_rag = GraphRAG(llm=llm, retriever=vc_retriever)"
   ],
   "id": "8e2cf317a83d59ae",
   "outputs": [],
   "execution_count": 19
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Lets start with  simple question and compare the answers for each",
   "id": "e772c5de32ef9bda"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:52:37.581520Z",
     "start_time": "2024-10-04T03:52:34.665576Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"What organ systems are most commonly affected by lupus? - provide a list\"\n",
    "print(f\"Vector Response: \\n{vector_rag.search(q, retriever_config={'top_k':3}).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':3}).answer}\")"
   ],
   "id": "477f00c916132357",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vector Response: \n",
      "The organ systems most commonly affected by lupus include:\n",
      "\n",
      "1. Skin\n",
      "2. Joints\n",
      "3. Kidneys (lupus nephritis)\n",
      "4. Blood cells\n",
      "5. Brain and central nervous system (neuropsychiatric involvement)\n",
      "6. Heart\n",
      "7. Lungs\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Lupus can affect various organ systems, including:\n",
      "\n",
      "1. Skin\n",
      "2. Joints\n",
      "3. Kidneys\n",
      "4. Blood cells\n",
      "5. Brain and central nervous system\n",
      "6. Heart\n",
      "7. Lungs\n"
     ]
    }
   ],
   "execution_count": 20
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Now lets try a bit more of a complex question",
   "id": "27fc4a28eec0d800"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-04T03:52:41.152010Z",
     "start_time": "2024-10-04T03:52:37.583435Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"Which biomarkers are associated with predicting organ damage in lupus patients? - provide a list\"\n",
    "print(f\"Vector Response: \\n{vector_rag.search(q).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q).answer}\")"
   ],
   "id": "52bf2c3383f67352",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vector Response: \n",
      "The context does not provide a specific list of biomarkers associated with predicting organ damage in lupus patients. However, it mentions the use of biomarkers to assess the main pathophysiologic pathway, predict risk of specific organ damage, and guide treatment and follow-up in lupus patients. For more detailed information, further research into specific studies or reviews on lupus biomarkers would be necessary.\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "The context provided does not explicitly mention specific biomarkers associated with predicting organ damage in lupus patients. However, it does mention that biomarkers express the condition of lupus, which may imply their potential role in assessing disease risk and progression, including organ damage. Additionally, the context discusses the use of autoantibodies as biomarkers for predicting neuropsychiatric events in systemic lupus erythematosus, which could be related to organ damage in the context of neuropsychiatric involvement. For a comprehensive list of specific biomarkers, further research or additional context would be needed.\n"
     ]
    }
   ],
   "execution_count": 21
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "",
   "id": "461dad8755e55348"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": "",
   "id": "b72a4184409b68ea",
   "outputs": [],
   "execution_count": null
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
